Twenty patients with reperfused acute myocardial infarction (AMI) received either an infusion of bone marrow-derived or circulating blood-derived progenitor cells. The conclusions show that intracoronary infusion of autologous progenitor cells is feasible, safe, and may benefit postinfarction remodeling and repair.
